ONO Introduces Carbon Neutral City Gas
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director: Gyo Sagara, “ONO”) announced that it has introduced carbon neutral city gas ("CN city gas") *1 from Tokyo Gas Co., Ltd. ("Tokyo Gas") to ONO’s Tsukuba Research Institute, and has joined the Carbon Neutral LNG Buyers Alliance *2.
This is the first introduction of CN city gas supplied by Tokyo Gas in the pharmaceutical industry.
Tsukuba Research Institute (Ibaraki)
Tsukuba Research Institute (Ibaraki)
Under the corporate philosophy of “Dedicated to the Fight against Disease and Pain,” ONO has been working to contribute to the realization of a healthier and sounder society by discovering and developing innovative pharmaceutical products.
We also have set our medium- and long-term environmental vision, “Environment Challenging Ono Vision (ECO VISION 2050),” and, as one of the priority issues, have set a target of reducing greenhouse gas emissions (Scope 1 + 2) to zero by the fiscal year 2050. The introduction of CN city gas this time is one of the effective measures to achieve our goals. We will consider introducing CN city gas to other sites in the future.
- Carbon neutral city gas:
City gas made from a type of liquefied natural gas (carbon-neutral LNG), which offsets greenhouse gases generated in the processes from the extraction to the burning of natural gas with carbon credits (carbon offset) and assumes that no CO2 is generated on a global scale. - Carbon Neutral LNG Buyers Alliance:
A partnership between Tokyo Gas, which procures and supplies CNL, and companies and corporations that purchase CNL, with the aim of expanding the use of CNL and increasing its value for a sustainable society.
A medium- and long-term environmental vision for 2050 "Environment Challenging Ono Vision (ECO VISION 2050)"
In the "ECO VISION 2050," ONO has set three priority issues: "Realization of a decarbonized society," "Realization of a water recycling society," and "Realization of a resource recycling society." For the realization of a decarbonized society, our medium- to long-term greenhouse gas reduction targets have been recognized as science-based evidence by the international initiative "Science Based Targets initiative (SBTi)." For Scope 1+2, our targets are classified by SBTi as the strictest “1.5°C target.”
For details of the ONO’s ESG initiatives, please refer to the following “Sustainability” in our website: https://sustainability.ono-pharma.com/en .